Sugi Predict

Sugi Predict / Compounds / SCHEMBL2139056

SCHEMBL2139056

SCHEMBL2139056

NC(=O)c1ccncc1N

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.70
▸ ALDH1A1 P00352 2/20 0.70
▸ TDP1 Q9NUW8 2/20 0.70
▸ KDM4C Q9H3R0 2/20 0.70
▸ MEN1 O00255 1/20 0.70
▸ KDM6B O15054 1/20 0.70
▸ KDM4A O75164 1/20 0.70
▸ MAPT P10636 1/20 0.70
▸ THRB P10828 1/20 0.70
▸ KMT2A Q03164 1/20 0.70
▸ KDM4D Q6B0I6 1/20 0.70
▸ L3MBTL1 Q9Y468 1/20 0.70
▸ GAA P10253 2/20 0.61
▸ GLA P06280 1/20 0.61
▸ SIRT3 Q9NTG7 2/20 0.57
▸ HTT P42858 1/20 0.46
▸ F7 P08709 1/20 0.45
▸ F3 P13726 1/20 0.45
▸ SARM1 Q6SZW1 1/20 0.45
▸ SIRT2 Q8IXJ6 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1643711 0.84 KDM4C (0.73) KDM4EALDH1A1TDP1KDM4CMEN1
SCHEMBL29643531 0.83 KDM4C (1.00) KDM4EALDH1A1TDP1KDM4CMEN1
SCHEMBL29270366 0.83 KDM4C (1.00) KDM4EALDH1A1TDP1KDM4CMEN1
SCHEMBL310266 0.83 TDP1 (0.62) KDM4EALDH1A1TDP1KDM4CMEN1
SCHEMBL535569 0.83 KDM4C (1.00) KDM4EALDH1A1TDP1KDM4CMEN1
SCHEMBL1330970 0.82 TDP1 (0.67) KDM4EALDH1A1TDP1KDM4CMEN1
SCHEMBL1687197 0.82 TDP1 (0.67) KDM4EALDH1A1TDP1KDM4CMEN1
SCHEMBL31139848 0.81 KDM4C (0.68) KDM4EALDH1A1TDP1KDM4CMEN1
Bromide SCHEMBL5768959 0.81 KDM4C (0.96) KDM4EALDH1A1TDP1KDM4CMEN1
Water SCHEMBL11483542 0.81 TDP1 (0.60) KDM4EALDH1A1TDP1KDM4CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3670490-B1 METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES KRATON POLYMERS LLC (US) 2023-01-18 — — EP claimed
US-10822302-B2 Method of purifying pine chemical compositions from aldehydes KRATON POLYMERS LLC (US) 2020-11-03 — — US claimed
EP-3670490-A1 METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES Kraton Polymers LLC (US) 2020-06-24 — — EP claimed
US-20200165191-A1 Method of Purifying Pine Chemical Compositions from Aldehydes KRATON POLYMERS LLC (US) 2020-05-28 — — US claimed
US-20260070889-A1 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE CHINA PHARMACEUTICAL UNIVERSITY (CN) 2026-03-12 — — US disclosed
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2025-02-27 — — US disclosed
US-12172998-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-12-24 — — US disclosed
CN-114621222-B 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors 诺华股份有限公司 2024-12-17 — — CN disclosed
US-20240174696-A1 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS GENENTECH, INC. (US) 2024-05-30 — — US disclosed
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors MITOBRIDGE, INC. (US) 2024-05-28 — — US disclosed
EP-4347594-A1 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS Genentech, Inc. (US) 2024-04-10 — — EP disclosed
EP-3615537-B1 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS NOVARTIS AG (CH) 2024-03-06 — — EP disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 — — US disclosed
EP-1363925-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2003-11-26 — — EP disclosed
WO-2002050091-A1 MACROLIDE ANTIBIOTICS GLAXO GROUP LIMITED (GB) 2002-06-27 — — WO disclosed
US-6391885-B1 CONTROLLING APOPTOSIS IN AUTOIMMUNE DISEASE CELL PATHWAYS, INC. 2002-05-21 — — US disclosed
US-6060477-A Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives CELL PATHWAYS, INC. (US) 2000-05-09 — — US disclosed
EP-0347146-B1 FUSED PYRIMIDINE DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1993-09-01 — — EP disclosed
US-5047404-A Fused pyrimidine derivatives bronchodilator agents, antiallergens SMITH KLINE & FRENCH LABORATORIES, LTD. (GB) 1991-09-10 — — US disclosed
EP-0347146-A2 Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1989-12-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993585-B2 Poly-ADP ribose polymerase (PARP) inhibitors PARP1, PARP2, PARP11 KDM4E 2486/4885ALDH1A1 203/4885TDP1 40/4885
US-12172998-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C KDM4E 17/4885ALDH1A1 392/4885TDP1 247/4885
US-20240174696-A1 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS LATS1, LATS2, GLS2 KDM4E 1411/4885ALDH1A1 2460/4885TDP1 1605/4885
US-20260070889-A1 5-PYRIDINE-1H-INDAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION, AND USE CSNK1A1, CSNK1A1L, CSNK2A3 KDM4E 2246/4885ALDH1A1 2405/4885TDP1 1809/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 KDM4E 1358/4885ALDH1A1 2482/4885TDP1 2834/4885
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C KDM4E 17/4885ALDH1A1 392/4885TDP1 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.